Partners Who Support the Implementation of the Grants

The Global Fund grants in Myanmar is being implemented through a network of partners.

National NGOs: Myanmar Medical Association, Myanmar Anti-Narcotics Association, Myanmar Health Assistant Association, Pyi Gyi Khin and the Union of Myanmar Federation of Chambers of Commerce and Industry;

International NGOs: Ammerican Refugee Committee, Burnet Institute, Clinton Health Access Initiative, Malteser International, International Union against Tuberculosis and Lung Disease, Medical Action Myanmar, Population Services International and Shoklo Malaria Research Unit;


Key Programme Achievements (2011- June 2020)

- 119,270 People receiving antiretroviral therapy
- 36.9+ Million Needles and syringes distributed to drug users
- 86.7+ Million Condoms distributed
- 1.3 million + Number of notified cases of all forms of TB
- 18,275 MDR-TB patients began second-line treatment
- 1.8 Million+ People treated for malaria
- 19.7 million + People tested for malaria
- 14.9 Million + Long lasting insecticidal nets distributed

A health provider from one of PR-UNOPS partners, Medical Action Myanmar (MAM) providing medicine to a patient. ©MAM

The Global Fund Programme in Myanmar
October 2021
The regional Tuberculosis Elimination among Migrants (TEAM) programme aims to reduce the TB burden among migrant populations in Cambodia, Lao PDR, Myanmar, Thailand, and Viet Nam. The Global Fund is financing the US$ 10 million programme for the period 2019–2021. The regional TEAM programme is focused around three main activities; case finding and treatment support to ensure migrants adhere to treatment; improving data collection and analytic work for advocacy and policy development at the regional level; and bilateral partnership building.

Through partnership with the Global Fund, UNOPS has assisted Myanmar in managing US$555.3 million worth of Global Fund grants over a ten-year period (2011–2020). UNOPS was again selected as a Principal Recipient (PR) to manage the new funding of US$261.6 million for the continuation of HIV, Malaria and TB programme implementation in Myanmar over the next three-year period (2021 - 2023). The grants from the Global Fund have allowed those most in need to better access prevention, care and treatment for HIV, TB and malaria.

UNOPS continues to serve as the Principal Recipient for the Regional Artemisinin-Resistance Initiative (RAI), which aims to escalate progress towards the elimination of malaria in Cambodia, Lao PDR, Myanmar, Thailand and Viet Nam. The Global Fund allocated US$ 176.3 million for the RAI grant for the period 2014–2017, which was expanded with a second phase, the RAI2-Elimination (RAI2E) programme, with a US$ 245.7 million regional grant over a three-year period (2018–2020), excluding Myanmar component.

The RAI is now being expanded for the coming three years (2021–2023) under the third phase, the RAI3-Elimination (RAI3E) with the grant approval value of US$ 228.3 million.

Since the outbreak of the COVID-19 pandemic in Myanmar, the Global Fund, through UNOPS as Principal Recipient, has been providing support for mitigation and response efforts. The Global Fund acknowledged the direct threat of the pandemic on people living with or affected by HIV, TB and malaria, and encouraged countries to reprogramme savings from existing grants in response to COVID-19. The Global Fund has pivoted total savings of US$ 7.1 million from its existing grants in Myanmar to support emergency procurement of necessary items to respond to COVID-19.

The Global Fund then approved additional funding under the COVID-19 Response Mechanism (C19RM). The C19RM is a new funding mechanism to support countries to respond adequately to COVID-19 and mitigate the impact on programmes to fight HIV, TB and malaria, and on health systems. The total funding that the Global Fund has provided under C19RM for 2020-2022 through PR-UNOPS was US$27.2 million.

In 2021, the Global Fund approved additional funding of US$ 91.6 million under C19RM. Therefore, the total C19RM budget becomes US$118.8 million from 2020 - 2023.